Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Merck Biosimilar To Take On Sanofi
by Ann M. Thayer
February 17, 2014
| A version of this story appeared in
Volume 92, Issue 7
Merck & Co. and its biosimilars partner Samsung Bioepis of South Korea have expanded their February 2013 collaboration to include a follow-on version of Sanofi’s diabetes drug Lantus (insulin glargine). Sanofi’s 2013 sales of the long-acting insulin analog totaled $7.8 billion. With its patent set to expire in 2015, Sanofi recently sued to block Eli Lilly & Co. from marketing a copycat version. Merck and Samsung expect to begin Phase III clinical trials soon with their version, MK-1293.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X